BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
ProPhase Labs, Inc. PRPH
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$4.3M
▼ 35.8% vs FY2024
EPS · FY25
$-1.74
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-271.5%
Net margin · FY25
-339.3%
Dividend coverage
1.3×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 4.3M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 339 cents on every revenue dollar this year.
Per share
USD -1.74
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 1.3 times — the rest stayed in the company.
Profitability
-271.5%
Return on equity, FY2025
ROE
Operating margin-415.4%
Net margin-339.3%
Return on assets-24.0%
Each USD of equity lost 271 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−21.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−67.2%
−21.4%
+5.6%
−7.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 59.9M
total assets, end of FY2025
Total assetsUSD 59.9M
EquityUSD 3.5M
CashUSD 90,000.00
Current ratio0.06×
Equity funds 6% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
−0.0
0.0
−0.0
0.0
·
0.0
−0.0
·
·
0.0
0.0
0.0
0.0
−0.0
−0.0
Net income $B
−0.0
−0.1
−0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.74
−26.68
−0.98
1.02
0.40
−0.18
−0.27
−0.15
2.59
−0.17
−0.22
−0.47
0.03
−0.07
−0.18
−0.25
−0.30
Dividend / sh $
·
·
·
·
0.30
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
−0
51
72
·
−185
−672
·
·
·
·
·
·
·
·
·
ROE %
−271.5
−188.1
−29.7
30.2
18.1
−19.5
−22.7
−7.2
214.7
−38.8
−36.8
−67.2
3.4
−9.6
−22.0
−25.4
−27.3
Shares out B
0.01
0.00
0.02
0.02
0.02
0.01
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
65 of 65
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed